Systematic review with network meta‐analysis: the efficacy of anti‐TNF agents for the treatment of Crohn's disease
Alimentary Pharmacology & Therapeutics2014Vol. 39(12), pp. 1349–1362
Citations Over TimeTop 1% of 2014 papers
Ryan W. Stidham, T. C. H. Lee, Peter Higgins, Amar R. Deshpande, Daniel A. Sussman, Amit G. Singal, B. Joseph Elmunzer, Sameer D. Saini, Sandeep Vijan, Akbar K. Waljee
Abstract
All anti-TNF agents are effective for induction and maintenance of response and remission in the treatment of CD. Although adalimumab is superior to certolizumab pegol for induction of remission, there is no evidence of clinical superiority among anti-TNF agents. Head-to-head trials among the anti-TNF agents are impractical in terms of size and cost.
Related Papers
- Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis.(2017)
- → Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn’s Disease(2015)9 cited
- → SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB(2017)14 cited
- → Benefit-Risk Assessment of the TNF-Antagonists Adalimumab and Certolizumab Pegol for Maintenance Treatment of Crohn's Disease(2011)
- [Place of biologic therapy in the treatment of inflammatory bowel diseases and assessment of its efficacy].(2013)